<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940976</url>
  </required_header>
  <id_info>
    <org_study_id>ESCC-A01</org_study_id>
    <nct_id>NCT03940976</nct_id>
  </id_info>
  <brief_title>Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)</brief_title>
  <official_title>Phase 2 Study of Afatinib in Previously Treated Recurrent or Metastasic Esophageal Squamous Cell Carcinoma With EGFR Overexpression or EGFR Amplification (ESCC-A01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 trial investigating the effect and safety of afatinib in previously treated
      recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EGFR
      amplification.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 28, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.</time_frame>
    <description>Percentage of patients who achieve partial response (PR) or complete response (CR) based on Response Evaluation Criteria In Solid Tumors (RECIST).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Related Adverse Events</measure>
    <time_frame>Until 30 days after the last treatment</time_frame>
    <description>Number of adverse events of afatinib in patients with ESCC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.</time_frame>
    <description>Percentage of patients who achieve partial response (PR) or complete response (CR) or stable disease (SD) based on Response Evaluation Criteria In Solid Tumors (RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Measure of time from study treatment to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Measure of time from study treatment to patient's death or lost to follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Afatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Afatinib is orally administered at 40mg Qd of each 28 day cycle.</description>
    <arm_group_label>Afatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Having signed informed consent.

          2. Age 18 to 70 years old.

          3. Histologically confirmed esophageal squamous carcinoma

          4. Immunohistochemistry confirmed EGFR(3+) or EGFR-FISH-amplification or next generation
             sequencing confirmed EGFR-amplification.

          5. Computed tomography (CT) or magnetic resonance imaging (MRI) confirmed unresectable
             metastasic or recurrent ESCC.

          6. Refractory or intolerant to at least one regimen.

          7. Measurable disease according to the Response Evaluation Criteria In Solid Tumors
             (RECIST) 1.1 criteria(diameter of the lesion should be more than 10mm by spiral CT or
             MRI, more than 20mm by common CT, the date of image should be less than 21 days before
             enrollment)

          8. Life expectancy of ≥3 month

          9. Eastern Cooperative Oncology Group (ECOG) 0-2

         10. WBC&gt;3,000/mm3, absolute neutrophil count ≥1500/mm3, platelet&gt;100,000/mm3,
             Hb&gt;9g/dl，Bilirubin level &lt; 1.5 times ULN，Serum creatinine &lt;1.5 times ULN，ALT and
             AST&lt;2.5 times ULN ，AKP &lt; 2.5 times ULN ，(≤5 times ULN in patients with liver
             metastases)(within 7 days before enrollment)

         11. No sever complication, such as active gastrointestinal bleeding, perforation,
             jaundice, obstruction, non-cancerous fever＞38℃.

         12. Good compliance

        Exclusion Criteria:

          1. Contraindications of afatinib.

          2. Unable to take afatinib orally because of esophageal stenosis.

          3. Currently receiving other effective regimens.

          4. Previous anticipate other clinical trial within 4 weeks before entering this study.

          5. No measurable lesions, eg. pleural fluid and ascites.

          6. With other malignancy within 5 year, except non-melanoma skin cancer and cervical
             carcinoma in situ.

          7. Heart failure or other sever organ dysfunction, eg. coronary artery disease,
             myocardial infarction within the last 6 months.

          8. Mentally abnormal or disable cognition,including central nervous system (CNS)
             metastasis.

          9. HIV infection, active hepatitis B or hepatitis C.

         10. Unstable systemic diseases such as poorly controlled diabetes.

         11. Interstitial lung disease, such as interstitial pneumonia, pulmonary fibrosis, or
             evidence of interstitial lung disease showed in X-ray/CT.

         12. Keratitis, ulcerative keratitis or severe dry eye syndrome. Known hypersensitivity to
             study drug.

         13. Pregnancy or lactation period.

         14. Active severe infection within 14 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Cancer Hospital and Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Cancer Hospital and Institute</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 28, 2019</study_first_submitted>
  <study_first_submitted_qc>May 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>June 9, 2019</last_update_submitted>
  <last_update_submitted_qc>June 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>afatinib</keyword>
  <keyword>EGFR Overexpression</keyword>
  <keyword>EGFR Amplification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

